GENETIC POLYMORPHISMS OF CYTOCHROME P450 2C9, VITAMIN K EPOXIDE-REDUCTASE SUBUNIT 1 AND WARFARIN DOSING IN PATIENTS WITH PERMANENT ATRIAL FIBRILLATION


Cite item

Full Text

Abstract

Aim - to assess the influence of genetic polymorphisms of CYP2C9 and VKORC1 on warfarin dosing in patients with permanent form of atrial fibrillation. Methods. The study included examination of 100 patients with coronary heart disease and permanent form of atrial fibrillation; mean age 60.5±5.8 years. Conclusion. In patients with permanent form of atrial fibrillation, genotypes CYP2C9*1/*3, TT and GG genotypes of VKORC1 are associated with low warfarin dose, compared to other genotypes. Genotype CYP2C9*1/*3 increases the risk of bleeding complication during warfarin therapy.

About the authors

A O Rubanenko

Samara State Medical University

Email: anatolii.rubanenko@gmail.com
PhD, teaching assistant at the Department of Propaedeutic Therapy of Samara State Medical University, doctor of functional diagnostics. p. 213, 25 Novo-Sadovaya st., Samara, Russia, 443110

Yu V Shchukin

Samara State Medical University

Email: samgmu_pt@mail.ru
PhD, Professor, head of the Department of Propaedeutic Therapy of Samara State Medical University.

References

  1. Camm AJ, Lip GYH, De Caterina R, Savelieva I, Atar D, Hohnloser SH, Hindricks G, Kirchhof P. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation. European heart journal. 2012; 33:2719-2747. doi:10.1093/ eurheart/ehs253
  2. Camm AJ, Kirchhof P, Lip GYH, Schotten U, Savelieva I. et al. Guidelines for the management of atrial fibrillation. European heart journal. 2010; 31:2369-2429. doi:10.1093/ eurheart/ehq278
  3. Militaru FC, Vesa SC, Pop TR, Buzoianu AD. Pharmacogenetics aspects of oral anticoagulants therapy. J. Med Life. 2015; 8(2):171-175
  4. Jiang NX, Ge JW, Xian YQ, Huang SY, Li YS. Clinical application of a new warfarin-dosing regimen based on the CYP2C9 and VKORC1 genotypes in atrial fibrillation patients. Biomed Rep. 2016; 4(4):453-458. doi: 10.3892/br.2016.617
  5. Bourgeois S, Jorgensen A, Zhang EJ, Hanson A, Gillman MS. et al. A multi-factorial analysis of response to warfarin in a UK prospective cohort. Genome Med. 2016; 8(1):1-12. doi: 10.1186/s13073-015-0255-y
  6. Kangelaris K, Bent S, Nussbaum R, Garcia DA, Tice JA. Genetic testing before anticoagulation? A systematic review of pharmacogenetic dosing of warfarin. Journal of General Internal Medicine. 2009; 24:656-664. doi: 10.1007/s11606-009-0949-1
  7. Wise ES, Gadomski SP. 2nd, McMaster WG. Jr., Wilson RJ, Nelms JK, Hocking KM, Brophy C.M. The influence of VKORC1 and CYP2C9 mutations on warfarin response after total hip and knee arthroplasty. J Orthop. 2015; 28(12) (Suppl 2):145-151. doi: 10.1016/j.jor.2015.10.023
  8. Poopak B, Rabieipoor S, Safari N, Naraghi E, Sheikhsofla F, Khosravipoor G. Identification of CYP2C9 and VKORC1 polymorphisms in Iranian patients who are under warfarin therapy. Int. J. Hematol. Oncol. Stem. Cell. Res. 2015; 9(4):185-192
  9. Klein TE, Altman RB, Eriksson N, Gage BF, Kimmel SE. et al. Estimation of the warfarin dose with clinical and pharmacogenetic data. New England Journal of Medicine. 2009; 360(8):753-764. doi: 10.1056/NEJMoa0809329
  10. Wadelius M, Chen LY, Downes K, Ghori J, Hunt S. et al. Common VKORC1 and GGCX polymorphisms associated with warfarin dose. Pharmacogenomics J. 2005; 5(4):262-270. doi: 10.1038/sj.tpj.6500313
  11. Chen W, Wu L, Liu X, Shen Y, Liang Y. et al. Warfarin dose requirement with different genotypes of polymorphisms on CYP2C9 and VKORC1 and indications in Han-Chinese patients. Int. J. Clin. Pharmacol. Ther. 2016; [Epub ahead of print]. doi: 10.5414/CP202494
  12. Lu Y, Yang J, Zhang H, Yang J. Prediction of warfarin maintenance dose in Han Chinese patients using a mechanistic model based on genetic and non-genetic factors. Clin. Pharmacokinet. 2013; 52(7):567-581. doi:10.1007/ s40262-013-0054-9
  13. Yang J, Chen Y, Li X, Wei X, Chen X. et al. Influence of CYP2C9 and VKORC1 genotypes on the risk of hemorrhagic complications in warfarin-treated patients: a systematic review and meta-analysis. Int. J. Cardiol. 2013; 168(4):4234-4243. doi: 10.1016/j.ijcard.2013.07.151

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2016 Rubanenko A.O., Shchukin Y.V.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

Согласие на обработку персональных данных

 

Используя сайт https://journals.rcsi.science, я (далее – «Пользователь» или «Субъект персональных данных») даю согласие на обработку персональных данных на этом сайте (текст Согласия) и на обработку персональных данных с помощью сервиса «Яндекс.Метрика» (текст Согласия).